The abstract is read at the publisher; the summary is JClub's.
PHGDH expression increases from PanIN to invasive pancreatic ductal adenocarcinoma, and PHGDH loss delays PDAC development while BI-9593 suppresses de novo serine synthesis and drives tumor regression.
- Why it matters: Limited clinical success of PHGDH inhibitors makes it critical to define how de novo serine synthesis functions across PDAC progression stages in human and mouse models.
- What they did: The study measured PHGDH across PanIN-to-invasive stages, used inducible PHGDH knockdown in genetically engineered mice, treated acutely with BI-9593, and applied stable isotope tracing plus metabolomics to map nutrient dependencies.
- The result: PHGDH-deficient tumors show reduced ASCT2 expression with impaired glutamine uptake and utilization, creating selective sensitivity to the glutamine antagonist DRP-104, without increased reliance on exogenous serine.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.